Anzeige
Erschienen in:
18.10.2021 | Brief Report
Circulating plasmablasts in children with steroid-sensitive nephrotic syndrome
Erschienen in: Pediatric Nephrology | Ausgabe 2/2022
Einloggen, um Zugang zu erhaltenAbstract
Background
The therapeutic efficacy of B cell–depleting anti-CD20 treatment in both pediatric and adult steroid-sensitive nephrotic syndromes (SSNS) suggests that B cells play a pathogenic role in the disease. In adults with minimal change disease (MCD), only circulating plasmablasts are increased during the active phase of the disease, among B cell subsets. These cells have not been studied yet in children with SSNS.
Methods
We retrospectively quantified by flow cytometry analysis circulating plasmablasts in 107 pediatric patients with SSNS (51 at disease onset, 27 during relapse, and 29 in remission). Data were compared with an equal number of age- and sex-matched healthy donors (HD).
Results
Circulating plasmablast levels, expressed as percentage of total CD19+ B cells or as percentage of total lymphocytes, were normal in all SSNS subgroups, compared to HD. Patients in remission had significantly fewer circulating plasmablasts compared to patients at disease onset. No significant correlation was observed between plasmablast levels and proteinuria or serum proteins, at onset. Treatment with prednisone and mycophenolate mofetil significantly reduced circulating levels of plasmablasts, unlike treatment with prednisone and calcineurin inhibitors.
Conclusions
The B cell phenotype of children with SSNS differs from that of adults with MCD. This may justify different therapeutic approaches.